secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001171843-24-004561
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline
--------------------------------------------------------------------------------

- Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.
- Recorded $40M loss contingency for advanced discussions to resolve SEC investigation.
- Cash $207.3M at June 30, 2024; no debt; warrants fully exercised.
- Phase 3 RETHINK-ALZ top-line data expected by end of 2024; REFOCUS-ALZ mid-2025.
- Audit Committee vacancy due to director death; Nasdaq noncompliance; cure until Aug 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/0001171843-24-004561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/f8k_080824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer